Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML3101

Sigma-Aldrich

MLi-2

≥98% (HPLC)

Synonym(s):

cis-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine, rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[(1-methylcyclopropyl)oxy]-1H-iIndazole

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H25N5O2
CAS Number:
1627091-47-7
Molecular Weight:
379.46
MDL number:
MFCD30536362
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

C[C@]([H])(O[C@@]([H])(C1)C)CN1C2=CC(C3=NNC(C3=C4)=CC=C4OC5(C)CC5)=NC=N2

InChI key

ATUUNJCZCOMUKD-OKILXGFUSA-N

Biochem/physiol Actions

MLi-2 is an orally available, CNS active, highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor. MLi-2 potently inhibits central and peripheral LRRK2 in mice.

Other Notes

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000286725
0000286725

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lindsey M Crown et al.
Frontiers in neurology, 11, 324-324 (2020-06-02)
Sleep disturbances co-occur with and precede the onset of motor symptoms in Parkinson's disease (PD). We evaluated sleep fragmentation and thalamocortical sleep spindles in mice expressing the p.G2019S mutation of the leucine-rich repeat kinase 2 (LRRK2) gene, one of the
Reika Watanabe et al.
Cell, 182(6), 1508-1518 (2020-08-14)
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of familial Parkinson's disease. LRRK2 is a multi-domain protein containing a kinase and GTPase. Using correlative light and electron microscopy, in situ cryo-electron tomography, and subtomogram analysis, we
Matthew J Fell et al.
The Journal of pharmacology and experimental therapeutics, 355(3), 397-409 (2015-09-27)
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of familial and sporadic Parkinson's disease (PD). That the most prevalent mutation, G2019S, leads to increased kinase activity has led to a concerted effort to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service